Clinical Trial Update: Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria [Phase 2]

View source ↗

Summary

Phase II trial of lonafarnib for Progeria (Hutchinson-Gilford Progeria syndrome) completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hutchinson-gilford Progeria Syndrome
• Progeria

Drugs mentioned

• Lonafarnib (lonafarnib)

Snippet

Sponsor: Monica E. Kleinman | Conditions: Progeria, Hutchinson-Gilford Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24